Although patients undergo procedures with curative intent for early‐stage hepatocellular carcinoma (HCC), up to 70% of patients may have disease recurrence in the liver at 5 years. Thus far, no therapy has proven to be effective in the adjuvant setting. Here, we discuss the application of immune‐based therapies in the adjuvant setting for HCC, focusing on the underlying rationale for immunotherapies, which patients may benefit from an immune‐based therapy, and what type of immune therapy should be implemented.

中文翻译：

---

肝细胞癌的辅助治疗：免疫治疗的前景

尽管患者接受了早期肝细胞癌 (HCC) 的治愈性手术，但高达 70% 的患者可能在 5 年内出现肝脏疾病复发。迄今为止，没有一种疗法被证明在辅助治疗中是有效的。在这里，我们讨论了基于免疫疗法在 HCC 辅助治疗中的应用，重点是免疫疗法的基本原理、哪些患者可以从基于免疫的疗法中受益，以及应该实施哪种类型的免疫疗法。